Conduzido em 01 Apr 2022 04:28 am
Professor Nicolas Mottet
Dr.Nicolas Mottet explains the evolution of treatment options for metastatic prostate cancer from ADT alone to addition of Docetaxel , Abiraterone , Enzalutamide & Apalutamide to ADT based on impact of these agents on treatment outcomes & quality of life based on review of data from individual clinical trials . Learn about impact of stratification based on volume of disease and risk categories on treatment outcomes for different agents.
